A strategic area of expertise for Ceva, canine cardiology has benefited from substantial R&D investment. Among other things, this investment has allowed the Group to develop, for the very first time in veterinary medicine, a molecule that was previously restricted to use in human cardiology: spironolactone.
More recently, Ceva was the first company proposing a combination of two actives (spironolactone and benazepril) for improving both the dogs quality of life and the treatment compliance.
End of 2013, Ceva reached a new step in its strategy of innovation in canine cardiology by acquiring the Sogeval company. With Sogeval joining the Ceva group, Ceva not only enlarged its product portfolio for canine Congestive Heart Failure (CHF) but also acquired new expertise in the development and the production of new drug formulations and innovative solutions for improving treatment compliance (e.g. clover scored shaped tablets for easy breaking ; …).